SCOTUS declines to review Enbrel biosimilar case, teeing up 30+ years of exclusivity and $20B more for Amgen’s blockbuster

As the House Oversight Committee is set to grill AbbVie CEO Richard Gonzalez on Tuesday over tactics to block competition for its best-selling drug of all time, another decision on Capitol Hill on Monday opened the door for billions more in Amgen profits over the next eight years. The Supreme…

...

Click to view original post